Vivos Therapeutics Inc. (NASDAQ: VVOS) stock gained by 9.98% during current market trading. Vivos Therapeutics is a medical technology business dedicated on developing and promoting novel diagnostic and therapy modalities for adult patients with sleep-disordered breathing, such as obstructive sleep apnea (OSA).
>> 7 Top Picks for the Post-Pandemic Economy <<
Current Update
Vivos Therapeutics has released updated information from an independent patient survey about its patented Vivos therapy for correcting oral tissue abnormalities and dentofacial deformities linked to OSA and other severe health problems.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The following are some of the key findings:
- The Vivos therapy for OSA was reported to have attained the expected effect by nearly all (97 percent) of the patients polled.
- Over half of the patients polled (63 percent) stated they rely on their dentist’s guidance to find a long-term solution that tackles the core cause of their OSA.
- Nearly a third (29%) of patients polled stated they were looking for non-surgical alternatives to current treatment options for OSA.
Many Vivos patients hope to see a considerable improvement in OSA and associated symptoms, while CPAP patient satisfaction and compliance rates are still low. According to some research, only 30 to 60% of people use CPAP, and if left untreated, OSA’s underlying problems can become chronic comorbidities, some of which can be fatal. The Vivos therapy, on the other hand, takes around 12 to 24 months to complete, after which most patients no longer require treatment.
>> 7 Top Picks for the Post-Pandemic Economy <<
Kirk Huntsman, Vivos Chairman and CEO stated,
Patients are the final judge of whether a therapy method has achieved the anticipated outcomes. This study confirms that people are in desperate need of a non-surgical, non-invasive, non-pharmaceutical, and low-cost treatment for their OSA. That is precisely the market niche that Vivos therapy addresses. The fact that virtually all of the patients polled said they had obtained their intended treatment result speaks volumes about their clinical and aesthetic outcomes. The technology just functions.
